Lauren Ostermann

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Collaborators (9)

Michael Andreeff

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

QI ZHANG

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Benjamin Ebert

Dana-Farber Cancer Institute

UNITED STATES

View details

Georgios Karras

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Natalia Baran

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Bing Carter

professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rasoul Pourebrahim

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jared Burks

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Steffen Boettcher

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lauren Ostermann

Research Interests

Explore related searches

Contact this professor

Articles (10)

Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia

Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia

Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.

Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Collaborators (9)

Michael Andreeff

QI ZHANG

Benjamin Ebert

Georgios Karras

Natalia Baran

Bing Carter

Rasoul Pourebrahim

Jared Burks

Steffen Boettcher

Make your next move.